| Literature DB >> 23365721 |
N F Renna1, C Lembo, E Diez, R M Miatello.
Abstract
(1) This study aims to demonstrate the causal involvement of renin angiotensin system (RAS) and oxidative stress (OS) on vascular inflammation in an experimental model of metabolic syndrome (MS) achieved by fructose administration to spontaneously hypertensive rats (FFHR) during 12 weeks. (2) Chronic treatment with candesartan (C) (10 mg/kg per day for the last 6 weeks) or 4OH-Tempol (T) (10(-3) mmol/L in drinking water for the last 6 weeks) reversed the increment in metabolic variables and systolic blood pressure. In addition, chronic C treatment reverted cardiovascular remodeling but not T. (3) Furthermore, chronic treatment with C was able to completely reverse the expression of NF-κB and VCAM-1, but T only reduced the expression. C reduced the expression of proatherogenic cytokines as CINC2, CINC3, VEGF, Leptin, TNF-alpha, and MCP-1 and also significantly reduced MIP-3, beta-NGF, and INF-gamma in vascular tissue in this experimental model. T was not able to substantially modify the expression of these cytokines. (4) The data suggest the involvement of RAS in the expression of inflammatory proteins at different vascular levels, allowing the creation of a microenvironment suitable for the creation, perpetuation, growth, and destabilization of vascular injury.Entities:
Year: 2013 PMID: 23365721 PMCID: PMC3556445 DOI: 10.1155/2013/420979
Source DB: PubMed Journal: Int J Hypertens Impact factor: 2.420
Metabolic and cardiovascular variables.
| Variable | WKY | FFR | SHR | FFHR | FFHR + C | FFHR + T |
|---|---|---|---|---|---|---|
| Fasting glucose (mmol/L) | 4.88 ± 0.1 | 6.44 ± 0.2* | 5.0 ± 0.2 | 6.5 ± 0.2∗ | 5.6 ± 0.1** | 5.6 ± 0.1** |
| Fasting triglycerides (mmol/L) | 0.8 ± 0.0 | 1.8 ± 0.0∗# | 0.9 ± 0.0 | 1.9 ± 0.1∗# | 1.1 ± 0.2** | 1.7 ± 0.1 |
| HOMA index | 4.32 ± 0.1 | 10.93 ± 0.1∗# | 7.2 ± 0.1* | 14.1 ± 0.4∗# | 5.7 ± 0.5** | 7.2 ± 0.1 |
| Area under glucose tolerance test curve | 881 ± 64 | 1392 ± 21∗# | 1292 ± 31* | 1839 ± 51∗# | 971 ± 54** | 1200 ± 2.4* |
| HDL-Cholesterol (mg/dL) | 22.5 ± 0.7 | 12.2 ± 0.8∗# | 19.3 ± 0.9* | 13.6 ± 1.2∗# | 19.2 ± 1.4** | 15.6 ± 2* |
| High-sensitivity C reactive Protein (mg/dL) | 2.55 ± 0.1 | 3.5 ± 0.0 | 3.1 ± 0.1 | 4.5 ± 0.1∗# | 2.01 ± 0.0** | 4.0 ± 0.0* |
| Systolic blood pressure (mmHg) | ||||||
| Baseline | 105 ± 3 | 102 ± 1.0 | 103 ± 1 | 105 ± 3 | 105 ± 2 | 103 ± 1 |
| 6 weeks | 113 ± 2.0 | 131 ± 3.0* | 161 ± 3* | 162 ± 2∗# | 165 ± 2* | 165 ± 2∗# |
| 12 weeks | 115 ± 1.3 | 136 ± 3.0* | 177 ± 1∗# | 181 ± 1∗# | 100 ± 2.5** | 168 ± 1.1 |
The above values correspond to metabolic and cardiovascular variables.
Symbols indicate: *P < 0.001 versus WKY; P < 0.001 versus SHR; # P < 0.01 versus FFR; **versus FFHR.
Oxidative stress and morphometric variables.
| Variable | W | FFR | SHR | FFHR | FFHR + C | FFHR + T |
|---|---|---|---|---|---|---|
| NAD(P)H oxidase activity | 40.5 ± 6 | 133 ± 5* | 160 ± 9.1∗# | 297 ± 9.1∗# | 142 ± 9.1∗ | 97 ± 2.1∗ |
| Arterial eNOS activity | 85.0 ± 2 | 60.1 ± 2.6* | 80.0 ± 2.1 | 56.4 ± 5.7∗# | 86.4 ± 1.1** | 84.6 ± 1.1** |
| TBARS ( | 1 ± 0.1 | 2.2 ± 0.1* | 1.69 ± 0.1* | 2.8 ± 0.1∗# | 1.03 ± 0.6# | 0.73 ± 0.4# |
| Relative heart weight | 225 ± 4 | 290 ± 4* | 330 ± 1.8∗# | 400 ± 4∗# | 262 ± 4** | 289 ± 4** |
| Myocardiocyte area ( | 1682 ± 69 | 2066 ± 57* | 2222 ± 78∗# | 3242 ± 55∗# | 1588 ± 55** | 2188 ± 35** |
| Media/Lumen ratio mesenteric arteries | 13.9 ± 0.3 | 10.2 ± 0.5* | 8.9 ± 0.6∗# | 8.45 ± 0.2∗# | 14.5 ± 5** | 9.5 ± 5** |
The above values correspond to stress oxidative and morphometrics variables.
Symbols indicate: *P < 0.001 versus WKY; P < 0.001 versus SHR; # P < 0.01 versus FFR; **versus FFHR.
Cytokine release profiles on different experimental models.
| Cytokinea | Relative levelsb | Array locationc | Fold increase for control group (WKY)d | ||||
|---|---|---|---|---|---|---|---|
| SHR | FFR | FFHR | FFHR + T | FFHR + C | |||
| CINC-2 | H | E1-2 | 1.18 | 1.10 | 2.42 | 2.07 | NC |
| CINC-3 | H | F1-2 | 1.34 | 1.30 | 2.74 | 2.00 | NC |
| CNTF | — | G1-2 | ~ | ~ | ~ | ~ | ~ |
| Fractalkine | — | H1-2 | ~ | ~ | ~ | ~ | ~ |
| GM-CSF | — | A4-5 | ~ | ~ | ~ | ~ | ~ |
| INF- | H | B3-4 | 5.00 | 4.50 | 5.90 | 4.00 | 1.50 |
| IL-1 | — | C3-4 | ~ | ~ | ~ | ~ | ~ |
| IL-1 | — | D3-4 | ~ | ~ | ~ | ~ | ~ |
| IL-4 | — | E3-4 | ~ | ~ | ~ | ~ | ~ |
| IL-6 | — | F3-4 | ~ | ~ | ~ | ~ | ~ |
| IL-10 | — | G3-4 | ~ | ~ | ~ | ~ | ~ |
| LIX | — | H3-4 | ~ | ~ | ~ | ~ | ~ |
| Leptin | H | A5-6 | 1.16 | 1.33 | 2.10 | 1.67 | NC |
| MCP-1 | H | B5-6 | 1.25 | NC | 4.00 | 2.62 | NC |
| MIP-3 | H | C5-6 | 1.16 | 1.33 | 3.91 | 2.50 | 1.25 |
|
| H | D5-6 | 2.40 | 2.40 | 3.50 | 2.93 | NC |
| TIMP-1 | H | E5-6 | 2.60 | 1.52 | 2.50 | 1.90 | NC |
| TNF- | H | F5-6 | 3.19 | 1.10 | 3.35 | 2.80 | 1.30 |
| VEGF | H | G5-6 | 2.50 | NC | 3.05 | 2.60 | NC |
aName of cytokine.
bRelative levels: —: undetectable; H: high; L: low.
cSee Figure 2 for the location of the duplicate spots in the matrix.
dWhen the control “~” symbol was used to indicate an approximation of zero, the values indicate the fold increase versus Wistar Kyoto (WKY: control group). NC: no change (less than or equal to fold difference from the level in WKY group).
ChemiArray Rat Lysate Cytokine Antibody Array I Map.
| A | B | C | D | E | F | G | H | |
|---|---|---|---|---|---|---|---|---|
| 1 | Positive | Positive | Negative | Negative | CINC-2 | CINC-3 | CNTF | Fractalkine |
| 2 | Positive | Positive | Negative | Negative | CINC-2 | CINC-3 | CNTF | Fractalkine |
| 3 | GM-CSF | INF- | IL-l | IL-l | IL-4 | IL-6 | IL-10 | LIX |
| 4 | GM-CSF | INF- | IL-l | IL-1 | IL-4 | IL-6 | IL-10 | LIX |
| 5 | Leptin | MCP-1 | MIP-3 |
| TIMP-1 | TNF- | VEGF | Blank |
| 6 | Leptin | MCP-1 | MIP-3 |
| TIMP-1 | TNF- | VEGF | Blank |
| 7 | Blank | Blank | Blank | Blank | Blank | Blank | Blank | Positive |
| 8 | Blank | Blank | Blank | Blank | Blank | Blank | Blank | Positive |
Cytokines Names: Neutrophil chemotactic cytokine 2 and 3 (CINC-2 and CINC-3), ciliary neurotrophic factor (CNFT), monocyte chemotactic protein-1 (MCP-1), inflammatory protein macrophage-3 alpha (MIP-3 alpha), nerve growth factor beta (beta-NGF), tissue inhibitor of metalloproteinase-1 (TIMP-1) and vascular endothelial growth factor (VEGF), granulocyte colony stimulating factor, macrophage (GM-CSF), interferon gamma (INF-γ), interleukin 1 alpha and beta (IL-1α, IL-1β), interleukin 4, 6, and 10 (IL-4, IL-6, IL-10), lipopolysaccharide-induced CXC chemokine (LIX or CXCL5), leptin, and tumor necrosis factor alpha (TNF-α).
Figure 2Detection of cytokines on membrane antibody arrays by chemiluminiscence. Each cytokine is represented by duplicate spots in the following locations. See Table 4. Average net light intensity for each pair of cytokine spots detected on the basis of gray-scale levels using US NIH Image software ver. 1.66. Cytokines names: Neutrophil chemotactic cytokine 2 and 3 (CINC-2 and CINC-3), ciliary neurotrophic factor (CNFT), monocyte chemotactic protein-1 (MCP-1), inflammatory protein macrophage-3 alpha (MIP-3 alpha), nerve growth factor beta (beta-NGF), tissue inhibitor of metalloproteinase-1 (TIMP-1) and vascular endothelial growth factor (VEGF), granulocyte colony stimulating factor, macrophage (GM-CSF), interferon gamma (INF-γ), interleukin 1 alpha and beta (IL-1α, IL-1β), interleukin 4, 6, and 10 (IL-4, IL-6, IL-10), lipopolysaccharide induced CXC chemokine (LIX or CXCL5), leptin, and tumor necrosis factor alpha (TNF-α).
Figure 1Cytoplasmatic and nuclear p-65 fraction of Nuclear Factor-κB (NF-κB) and Vascular cell adhesion protein 1 (VCAM-1) expression in mesenteric arteries by western blot and Inmunohistochemistry. In up panel shows the western blot representative membrane in which analyzed anti-VCAM-1-FITC and anti-p65-TRITC, the results were obtained by optic density of the bands revealed for each group. In top panel shows microphotographs obtained by laser ICM 600x of mesenteric tissue.